- Home
- PYXS vs TCRX Comparison
PYXS vs TCRX Comparison
Compare PYXS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- TCRX
- Stock Information
- Founded
- PYXS 2018
- TCRX 2018
- Country
- PYXS United States
- TCRX United States
- Employees
- PYXS N/A
- TCRX N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- TCRX Health Care
- Exchange
- PYXS Nasdaq
- TCRX Nasdaq
- Market Cap
- PYXS 79.4M
- TCRX 91.7M
- IPO Year
- PYXS 2021
- TCRX 2021
- Fundamental
- Price
- PYXS $2.21
- TCRX $1.60
- Analyst Decision
- PYXS Strong Buy
- TCRX Strong Buy
- Analyst Count
- PYXS 5
- TCRX 5
- Target Price
- PYXS $7.75
- TCRX $9.40
- AVG Volume (30 Days)
- PYXS 900.3K
- TCRX 219.1K
- Earning Date
- PYXS 11-11-2025
- TCRX 11-11-2025
- Dividend Yield
- PYXS N/A
- TCRX N/A
- EPS Growth
- PYXS N/A
- TCRX N/A
- EPS
- PYXS N/A
- TCRX N/A
- Revenue
- PYXS $2,820,000.00
- TCRX $6,961,000.00
- Revenue This Year
- PYXS N/A
- TCRX $255.18
- Revenue Next Year
- PYXS N/A
- TCRX N/A
- P/E Ratio
- PYXS N/A
- TCRX N/A
- Revenue Growth
- PYXS N/A
- TCRX N/A
- 52 Week Low
- PYXS $0.83
- TCRX $1.02
- 52 Week High
- PYXS $5.39
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- PYXS 79.60
- TCRX 36.40
- Support Level
- PYXS $1.76
- TCRX $1.73
- Resistance Level
- PYXS $2.00
- TCRX $1.96
- Average True Range (ATR)
- PYXS 0.18
- TCRX 0.11
- MACD
- PYXS 0.05
- TCRX -0.03
- Stochastic Oscillator
- PYXS 90.38
- TCRX 0.00
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.